Health Insurers May Be Contributing to the Opioid Crisis in the United States
Posted 09/18/17
By the C|C Whistleblower Lawyer Team
An article in the New York Times describes the role health insurers may be playing in perpetuating the opioid crisis in the United States. The argument is that health insurers are limiting access to pain medications that have a lower risk of dependency. The reason is that opioid drugs are generally cheaper and less risky alternatives are more expensive. The New York State...
By the C|C Whistleblower Lawyer Team
This week's Department of Justice "Catch of the Week" goes to Novo Nordisk Inc. On Tuesday, the company agreed to pay $58.65 million to settle charges it violated the 
By the C|C Whistleblower Lawyer Team
Last Friday, the Department of Justice (“DOJ”) 
By the C|C Whistleblower Lawyer Team
This week's Department of Justice "Catch of the Week" goes to Mylan Inc. and Mylan Specialty L.P. Yesterday, the pharmaceutical companies agreed to pay $465 million to settle charges they violated the 
By the C|C Whistleblower Lawyer Team
A recent New York Times 
By the C|C Whistleblower Lawyer Team
Pharmaceutical manufacturer Celgene Corp. agreed to pay $280 million to settle claims that it illegally promoted two cancer drugs, Thalomid and Revlimid, for unapproved uses. The case was filed by a former Celgene sales representative under the 
By 
By the C|C Whistleblower Lawyer Team
Hundreds of people nationwide, including dozens of doctors, have been charged in health care fraud prosecutions, accused of collectively defrauding the government of $1.3 billion. Nearly one-third of the 412 charged were accused of opioid-related crimes. The health care providers, about 50 of them doctors, billed Medicare and Medicaid for drugs that were never purchased;...
By the C|C Whistleblower Lawyer Team
On Wednesday, opening statements were delivered in the trial of Martin Shkreli, the “pharma bro” who is best known for his fiftyfold price increase of the lifesaving HIV/AIDS drug Daraprim while CEO of Turing Pharmaceuticals. Shkreli is being tried, however, on several counts of securities and wire fraud dating from his time running the hedge funds MSMB Capital and MSMB...
By the C|C Whistleblower Lawyer Team
The owner and director of compliance of an Indiana compounding pharmacy were charged criminally in connection with their distribution of over- and under-potent drugs, and defrauding the United States by interfering with and obstructing the lawful functions of the FDA.
Paul J. Elmer, 64, of Fishers, Indiana, and Caprice R. Bearden, 62, of Carmel, Indiana, were charged in a...